Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 3Endocrine 3Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 25Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Mesothelioma 2Stomach Neoplasms 1Sarcoma 1SCLC, Extensive Stage 1Recurrence 1Ovarian Neoplasms 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Nivolumab 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2fludarabine 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2Everolimus 2Carboplatin 2tislelizumab 1taxane 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1olaparib 1liposomal doxorubicin 1entrectinib 1cabozantinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1RRx-001 1Quality of Life 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × PM 01183 × Thoracic × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡